Sun J, Halfvarson J, Bergman D, et al. Statin use and risk of colorectal cancer in patients with inflammatory bowel disease. EClinicalMedicine. 2023;63:102182.
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
Waldum H, Fossmark R. Inflammation and digestive cancer. Int J Mol Sci. 2023;24(17):13503.
Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(4):24–30.
Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41.
Porter RJ, Arends MJ, Churchhouse A, et al. Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines. J Crohn’s Colitis. 2021. https://doi.org/10.1093/ecco-jcc/jjab102.
Soomro S, Venkateswaran S, Vanarsa K, et al. Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen. Nat Commun. 2021;12(1):1–11.
Gasparetto M, Payne F, Nayak K, et al. Transcription and DNA methylation patterns of blood-derived CD8+ T cells are associated with age and inflammatory bowel disease but do not predict prognosis. Gastroenterology. 2021;160(1):232-44.e7.
Fazio A, Bordoni D, Kuiper JW, et al. DNA methyltransferase 3A controls intestinal epithelial barrier function and regeneration in the colon. Nat Commun. 2022;13(1):1–19.
Hirsch D, Hardt J, Sauer C, et al. Molecular characterization of ulcerative colitis-associated colorectal carcinomas. Mod Pathol. 2021;34(6):1153–66.
Rajamäki K, Taira A, Katainen R, et al. Genetic and epigenetic characteristics of inflammatory bowel disease associated colorectal cancer. Gastroenterology. 2021. https://doi.org/10.1053/j.gastro.2021.04.042.
Li J, Ma X, Chakravarti D, et al. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021;35(11–12):787–820.
Matsumoto K, Urabe Y, Oka S, et al. Genomic landscape of early-stage colorectal neoplasia developing from the ulcerative colitis mucosa in the Japanese population. Inflamm Bowel Dis. 2021;27(5):686–96.
Huang D, Sun W, Zhou Y, et al. Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. 2018;37(1):173–87.
Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107(2):369.
Aust DE, Terdiman JP, Willenbucher RF, et al. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer. 2002;94(5):1421–7.
Wei M, Ma Y, Shen L, et al. NDRG2 regulates adherens junction integrity to restrict colitis and tumourigenesis. EBioMedicine. 2020;61:103068.
Kumar A, Priyamvada S, Ge Y, et al. A novel role of SLC26A3 in the maintenance of intestinal epithelial barrier integrity. Gastroenterology. 2021;160(4):1240-55.e3.
Grosheva I, Zheng D, Levy M, et al. High-throughput screen identifies host and microbiota regulators of intestinal barrier function. Gastroenterology. 2020;159(5):1807–23.
Spalinger MR, Sayoc-Becerra A, Santos AN, et al. PTPN2 regulates interactions between macrophages and intestinal epithelial cells to promote intestinal barrier function. Gastroenterology. 2020;159(5):1763-77.e14.
Sahoo D, Swanson L, Sayed IM, et al. Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease. Nat Commun. 2021;12(1):1–14.
Grivennikov S, Karin E, Terzic J, et al. IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis associated cancer. Cancer Cell. 2009;15(2):103–13.
Meir M, Burkard N, Ungewiß H, et al. Neurotrophic factor GDNF regulates intestinal barrier function in inflammatory bowel disease. J Clin Investig. 2019;129(7):2824–40.
Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392.
Hidalgo García L, Molina Tijeras JA, Huertas Peña FJ, et al. Intestinal mesenchymal cells regulate immune responses and promote epithelial regeneration in vitro and in dextran sulfate sodium-induced experimental colitis in mice. Acta Physiol. 2021. https://doi.org/10.1111/apha.13699.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539.
Zhu W, Miyata N, Winter MG, et al. Editing of the gut microbiota reduces carcinogenesis in mouse models of colitis-associated colorectal cancer. J Exp Med. 2019;216(10):2378–93.
Cohen LJ, Cho JH, Gevers D, et al. Genetic factors and the intestinal microbiome guide development of microbe-based therapies for inflammatory bowel diseases. Gastroenterology. 2019;156(8):2174–89.
López-Posadas R, Neurath MF, Atreya I. Molecular pathways driving disease-specific alterations of intestinal epithelial cells. Cell Mol Life Sci. 2017;74(5):803–26.
Hu S, Venema WTU, Westra H-J, et al. Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease. Nat Commun. 2021;12(1):1–10.
Xiao L, Li X-X, Chung HK, et al. RNA-binding protein HuR regulates Paneth cell function by altering membrane localization of TLR2 via post-transcriptional control of CNPY3. Gastroenterology. 2019;157(3):731–43.
Yu S, Balasubramanian I, Laubitz D, et al. Paneth cell-derived lysozyme defines the composition of mucolytic microbiota and the inflammatory tone of the intestine. Immunity. 2020;53(2):398-416.e8.
Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2015;14(1):20–32.
Banerjee A, Herring CA, Chen B, et al. Succinate produced by intestinal microbes promotes specification of tuft cells to suppress ileal inflammation. Gastroenterology. 2020;159(6):2101-155.e5.
Balasubramanian I, Gao N. From sensing to shaping microbiota: insights into the role of NOD2 in intestinal homeostasis and progression of Crohn’s disease. Am J Physiol Gastrointest Liver Physiol. 2017;313(1):G7–13.
Landi MT, Bishop DT, MacGregor S, et al. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nat Genet. 2020;52(5):494–504.
Liu Z-Y, Zheng M, Li Y-M, et al. RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression. Theranostics. 2019;9(12):3659.
Zhou M, He J, Shi Y, et al. ABIN3 negatively regulates necroptosis-induced intestinal inflammation through recruiting A20 and restricting the ubiquitination of RIPK3 in inflammatory bowel disease. J Crohns Colitis. 2021;15(1):99–114.
Kosinsky RL, Saul D, Ammer-Herrmenau C, et al. USP22 suppresses sparc expression in acute colitis and inflammation-associated colorectal cancer. Cancers. 2021;13(8):1817.
Powell N, Pantazi E, Pavlidis P, et al. Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells. Gut. 2020;69(3):578–90.
Perez LG, Kempski J, McGee HM, et al. TGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer. Nat Commun. 2020;11(1):1–14.
Sheng YH, Giri R, Davies J, et al. A nucleotide analog prevents colitis-associated cancer via beta-catenin independently of inflammation and autophagy. Cell Mol Gastroenterol Hepatol. 2021;11(1):33–53.
Hibiya S, Tsuchiya K, Hayashi R, et al. Long-term inflammation transforms intestinal epithelial cells of colonic organoids. J Crohns Colitis. 2017;11(5):621–30.
De Salvo C, Buela K-A, Creyns B, et al. NOD2 drives early IL-33–dependent expansion of group 2 innate lymphoid cells during Crohn’s disease–like ileitis. J Clin Invest. 2021;131(5):e140624.
Solà-Tapias N, Vergnolle N, Denadai-Souza A, et al. The interplay between genetic risk factors and proteolytic dysregulation in the pathophysiology of inflammatory bowel disease. J Crohns Colitis. 2020;14(8):1149–61.
Lee M, Kim Y-S, Lim S, et al. Protein stabilization of ITF2 by NF-κB prevents colitis-associated cancer development. Nat Commun. 2023;14(1):2363.
Kakiuchi N, Yoshida K, Uchino M, et al. Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature. 2020;577(7789):260–5.
Tian H, Qian J, Ai L, et al. Upregulation of ASAP 3 contributes to colorectal carcinogenesis and indicates poor survival outcome. Cancer Sci. 2017;108(8):1544–55.
Li Q, Chen Y, Zhang D, et al. IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer. JCI insight. 2019;4(19):e130867.
Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(6):323–37.
Lamichhane S, Mo J-S, Sharma G, et al. MicroRNA 452 regulates IL20RA-mediated JAK1/STAT3 pathway in inflammatory colitis and colorectal cancer. Inflamm Res. 2021;70(8):903–14.
Willson TA, Jurickova I, Collins M, et al. Deletion of intestinal epithelial cell STAT3 promotes T-lymphocyte STAT3 activation and chronic colitis following acute dextran sodium sulfate injury in mice. Inflamm Bowel Dis. 2013;19(3):512.
Pang L, Huynh J, Alorro MG, et al. STAT3 signalling via the IL-6ST/gp130 cytokine receptor promotes epithelial integrity and intestinal barrier function during DSS-induced colitis. Biomedicines. 2021;9(2):187.
Josa V, Ferenczi S, Szalai R, et al. Thrombocytosis and effects of IL-6 knock-out in a colitis-associated cancer model. Int J Mol Sci. 2020;21(17):6218.
Backert I, Koralov SB, Wirtz S, et al. STAT3 activation in Th17 and Th22 cells controls IL-22-mediated epithelial host defense during infectious colitis. J Immunol. 2014;193(7):3779.
Keir ME, Yi T, Lu TT, et al. The role of IL-22 in intestinal health and disease. J Exp Med. 2020;217(3):e20192195.
Aden K, Tran F, Ito G, et al. ATG16L1 orchestrates interleukin-22 signaling in the intestinal epithelium via cGAS–STING. J Exp Med. 2018;215(11):2868–86.
Delgado-Ramirez Y, Baltazar-Perez I, Martinez Y, et al. STAT1 is required for decreasing accumulation of granulocytic cells via IL-17 during initial steps of colitis-associated cancer. Int J Mol Sci. 2021;22(14):7695.
Liu X, Wei W, Li X, et al. BMI1 and MEL18 promote colitis-associated cancer in mice via REG3B and STAT3. Gastroenterology. 2017;153(6):1607.
Ma X, Meng Z, Jin L, et al. CAMK2γ in intestinal epithelial cells modulates colitis-associated colorectal carcinogenesis via enhancing STAT3 activation. Oncogene. 2017;36(28):4060–71.
Ye X, Wu H, Sheng L, et al. Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling. Nat Commun. 2019;10(1):1–15.
Lin X, Sun Q, Zhou L, et al. Colonic epithelial mTORC1 promotes ulcerative colitis through COX-2-mediated Th17 responses. Mucosal Immunol. 2018;11(6):1663–73.
Rizzo A, Di Giovangiulio M, Stolfi C, et al. RORγt-expressing Tregs drive the growth of colitis-associated colorectal cancer by controlling IL6 in dendritic cells. Cancer Immunol Res. 2018;6(9):1082–92.
Schreiber S, Aden K, Bernardes JP, et al. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. 2021;160(7):2354-66.e11.
Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.
Robles AI, Traverso G, Zhang M, et al. Whole-exome sequencing analyses of inflammatory bowel disease-associated colorectal cancers. Gastroenterology. 2016;150(4):931.
Sakai K, De Velasco MA, Kura Y, et al. Transcriptome profiling and metagenomic analysis help to elucidate interactions in an inflammation-associated cancer mouse model. Cancers. 2021;13(15):3683.
Biscaglia G, Latiano A, Castellana S, et al. Germline alterations in patients with IBD-associated colorectal cancer. Inflamm Bowel Dis. 2021. https://doi.org/10.1093/ibd/izab195.
Mäki-Nevala S, Ukwattage S, Olkinuora A, et al. Somatic mutation profiles as molecular classifiers of ulcerative colitis-associated colorectal cancer. Int J Cancer. 2021;148(12):2997–3007.
Kesari MV, Gaopande VL, Joshi AR, et al. Immunohistochemical study of MUC1, MUC2 and MUC5AC in colorectal carcinoma and review of literature. Indian J Gastroenterol Off J Indian Soc Gastroenterol. 2015;34(1):63–7.
Li W, Zhang N, Jin C, et al. MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI insight. 2020;5(12):e137112.
Peng K, Kou L, Yu L, et al. Histone demethylase JMJD2D interacts with β-catenin to induce transcription and activate colorectal cancer cell proliferation and tumor growth in mice. Gastroenterology. 2019;156(4):1112–26.
Zhuo M, Chen W, Shang S, et al. Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling. Oncogene. 2020;39(16):3336–53.
Hua F, Shang S, Yang Y-w, et al. TRIB3 interacts with β-catenin and TCF4 to increase stem cell features of colorectal cancer stem cells and tumorigenesis. Gastroenterology. 2019;156(3):708-21.e15.
Zeng S, Chen L, Sun Q, et al. Scutellarin ameliorates colitis-associated colorectal cancer by suppressing Wnt/β-catenin signaling cascade. Eur J Pharmacol. 2021;906:174253.
Wu H, Wu Z, Qiu Y, et al. Supplementing a specific synbiotic suppressed the incidence of AOM/DSS-induced colorectal cancer in mice. iScience. 2023. https://doi.org/10.1016/j.isci.2023.106979.
Južnić L, Peuker K, Strigli A, et al. SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation. Gut. 2021;70(3):485–98.
Wang Q, Wang Z, Zhang Z, et al. Landscape of cell heterogeneity and evolutionary trajectory in ulcerative colitis-associated colon cancer revealed by single-cell RNA sequencing. Chin J Cancer Res. 2021;33(2):271.
Hirano T, Hirayama D, Wagatsuma K, et al. Immunological mechanisms in inflammation-associated colon carcinogenesis. Int J Mol Sci. 2020;21(9):3062.
Coskun M. TNF-a-induced down-regulation of CDX2 suppresses MEP1A expression in colitis. Biochimica Biophysica Acta Molecular Basis Dis. 2014;1822(6):843–51.
Ahn SH, Shah YM, Junko Inoue MS, et al. Hepatocyte nuclear factor 4α in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(7):908–20.
Liang W, Peng X, Li Q, et al. FAM3D is essential for colon homeostasis and host defense against inflammation associated carcinogenesis. Nat Commun. 2020;11(1):1–16.
Liu M, Sun T, Li N, et al. BRG1 attenuates colonic inflammation and tumorigenesis through autophagy-dependent oxidative stress sequestration. Nat Commun. 2019;10(1):1–15.
Liu M, Rao H, Liu J, et al. The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis. Redox Biol. 2021;43:102004.
Muise AM, Walters TD, Glowacka WK, et al. Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn’s disease. Gut. 2009;58(8):1121–7.
Henriques A, Koliaraki V, Kollias G. Mesenchymal MAPKAPK2/HSP27 drives intestinal carcinogenesis. Proc Natl Acad Sci. 2018;115(24):E5546–55.
Powell DW, Pinchuk IV, Saada JI, et al. Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol. 2011;73(1):213–37.
Kinchen J, Chen HH, Parikh K, et al. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. Cell. 2018;175(2):372-86.e17.
Kienzl M, Hasenoehrl C, Valadez-Cosmes P, et al. IL-33 reduces tumor growth in models of colorectal cancer with the help of eosinophils. Oncoimmunology. 2020;9(1):1776059.
Cortez E, Roswall P, Pietras K. Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol. 2014;25(2):3–9.
Abolarinwa BA, Ibrahim RB, Huang Y-H. Conceptual development of immunotherapeutic approaches to gastrointestinal cancer. Int J Mol Sci. 2019;20(18):4624.
Tommelein J, Verset L, Boterberg T, et al. Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front Oncol. 2015;5:63.
Darby IA, Laverdet B, Bonté F, et al. Fibroblasts and myofibroblasts in wound healing. Clin Cosmet Investig Dermatol. 2014;7:301.
Gomes RN, Manuel F, Nascimento DS. The bright side of fibroblasts: molecular signature and regenerative cues in major organs. NPJ Regen Med. 2021;6(1):1–12.
Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res. 2010;316(17):2713–22.
Boesch M, Baty F, Rumpold H, et al. Fibroblasts in cancer: defining target structures for therapeutic intervention. Biochimica Biophysica Acta Rev Cancer. 2019;1872(1):111–21.
Ma H, Wang J, Zhao X, et al. Periostin promotes colorectal tumorigenesis through integrin-FAK-Src pathway-mediated YAP/TAZ activation. Cell reports. 2020;30(3):793-806.e6.
Nishina T, Deguchi Y, Ohshima D, et al. Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer. Nat Commun. 2021;12(1):1–20.
Marsh T, Pietras K, McAllister SS. Fibroblasts as architects of cancer pathogenesis. Biochimica Biophysica Acta Molecular Basis Dis. 2013;1832(7):1070–8.
Servais C, Erez N. From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J Pathol. 2013;229(2):198–207.
Mifflin RC, Pinchuk IV, Saada JI, et al. Intestinal myofibroblasts: targets for stem cell therapy. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):G684–96.
Yuan Q, Gu J, Zhang J, et al. MyD88 in myofibroblasts enhances colitis-associated tumorigenesis via promoting macrophage M2 polarization. Cell Rep. 2021;34(5):108724.
Boire A, Covic L, Agarwal A, et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120(3):303–13.
Roulis M, Armaka M, Manoloukos M, et al. Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proc Natl Acad Sci. 2011;108(13):5396–401.
Diez-Obrero V, Moratalla-Navarro F, Ibañez-Sanz G, et al. Transcriptome-wide association study for inflammatory bowel disease reveals novel candidate susceptibility genes in specific colon subsites and tissue categories. J Crohn’s Colitis. 2021;16(2):275–85.
Kim Y-G, Kamada N, Shaw MH, et al. The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity. 2011;34(5):769–80.
Lin J-D, Devlin JC, Yeung F, et al. Rewilding Nod2 and Atg16l1 mutant mice uncovers genetic and environmental contributions to microbial responses and immune cell composition. Cell host & microbe. 2020;27(5):830-40.e4.
Roulis M, Nikolaou C, Kotsaki E, et al. Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis. Proc Natl Acad Sci. 2014;111(43):E4658–67.
Ohlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014;211(8):1503–23.
Gregorieff A, Pinto D, Begthel H, et al. Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology. 2005;129(2):626–38.
McCarthy N, Manieri E, Storm EE, et al. Distinct mesenchymal cell populations generate the essential intestinal BMP signaling gradient. Cell Stem Cell. 2020;26(3):391-402.e5.
Rupp C, Scherzer M, Rudisch A, et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor–stroma interaction. Oncogene. 2015;34(7):815.
Ren J, Ding L, Zhang D, et al. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8(14):3932.
Hawinkels LJ, Paauwe M, Verspaget HW, et al. Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts. Oncogene. 2014;33(1):97–107.
Koliaraki V, Pasparakis M, Kollias G. IKKβ in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J Exp Med. 2015;212(13):2235–51.
Pallangyo CK, Ziegler PK, Greten FR. IKKβ acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis. J Exp Med. 2015;212(13):2253–66.
Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15(12):786–801.
Levi-Galibov O, Lavon H, Wassermann-Dozorets R, et al. Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer. Nat Commun. 2020;11(1):1–19.
Heichler C, Schmied A, Enderle K, et al. Targeting STAT3 signaling in COL1+ fibroblasts controls colitis-associated cancer in mice. Cancers. 2022;14(6):1472.
Gao L, Yu Q, Zhang H, et al. A resident stromal cell population actively restrains innate immune response in the propagation phase of colitis pathogenesis in mice. Sci Transl Med. 2021;13(603):eabb5071.
Thomson CA, Nibbs RJ, McCoy KD, et al. Immunological roles of intestinal mesenchymal cells. Immunology. 2020;160(4):313–24.
Walton KL, Holt L, Sartor RB. Lipopolysaccharide activates innate immune responses in murine intestinal myofibroblasts through multiple signaling pathways. Am J Physiol Gastroint Liver Physiol. 2009;296(3):601–11.
Horiguchi H, Kadomatsu T, Miyata K, et al. Stroma-derived ANGPTL2 establishes an anti-tumor microenvironment during intestinal tumorigenesis. Oncogene. 2021;40(1):55–67.
Stadler M, Pudelko K, Biermeier A, et al. Stromal fibroblasts shape the myeloid phenotype in normal colon and colorectal cancer and induce CD163 and CCL2 expression in macrophages. Cancer Lett. 2021. https://doi.org/10.1016/j.canlet.2021.07.006.
Kobayashi H, Gieniec KA, Lannagan TR, et al. The origin and contribution of cancer-associated fibroblasts in colorectal carcinogenesis. Gastroenterology. 2022;162(3):890–906.
Herrera M, Herrera A, DomãNguez G, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Science. 2013;104(4):437–44.
Torres S, Bartolomé RA, Mendes M, et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res. 2013;19(21):6006–19.
Geremia A, Arancibia-Cárcamo CV. Innate lymphoid cells in intestinal inflammation. Front Immunol. 2017;8:1296.
Mitsialis V, Wall S, Liu P, et al. Single-cell analyses of colon and blood reveal distinct immune cell signatures of ulcerative colitis and Crohn’s disease. Gastroenterology. 2020;159(2):591-608.e10.
Li Z-W, Sun B, Gong T, et al. GNAI1 and GNAI3 reduce colitis-associated tumorigenesis in mice by blocking IL6 signaling and down-regulating expression of GNAI2. Gastroenterology. 2019;156(8):2297–312.
Na YR, Stakenborg M, Seok SH, et al. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol. 2019;16(9):531–43.
Galon J, Costes A, Sanchezcabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4.
Leite CA, Mota JM, de Lima KA, et al. Paradoxical interaction between cancer and long-term postsepsis disorder: impairment of de novo carcinogenesis versus favoring the growth of established tumors. J Immunother Cancer. 2020;8(1):e000129.
Ortiz ML, Kumar V, Martner A, et al. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17–producing CD4+ T cells. J Exp Med. 2015;212(3):351–67.
Liao Y, Zhao J, Bulek K, et al. Inflammation mobilizes copper metabolism to promote colon tumorigenesis via an IL-17-STEAP4-XIAP axis. Nat Commun. 2020;11(1):1–15.
Karagiannidis I, Jerman SJ, Jacenik D, et al. G-CSF and G-CSFR modulate CD4 and CD8 T cell responses to promote colon tumor growth and are potential therapeutic targets. Front Immunol. 2020;11:1885.
Liu C, Liu R, Wang B, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021;9(1):e001895.
Itatani Y, Yamamoto T, Zhong C, et al. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proc Natl Acad Sci. 2020;117(35):21598–608.
Belarif L, Danger R, Kermarrec L, et al. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Investig. 2019;129(5):1910–25.
Olesch C, Sirait-Fischer E, Berkefeld M, et al. S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion. J Clin Investig. 2020;130(10):5461–76.
Abu-Sbeih H, Faleck DM, Ricciuti B, et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol. 2020;38(6):576.
Zundler S, Becker E, Schulze LL, et al. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut. 2019;68(9):1688–700.
Sasson SC, Slevin SM, Cheung VT, et al. IFNγ-producing CD8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology. 2021. https://doi.org/10.1053/j.gastro.2021.06.025.
Shi Y, Fu Y, Zhang X, et al. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer. Cancer Immunol Immunother. 2021;70(1):61–73.
Endo Y, Marusawa H, Kou T, et al. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology. 2008;135(3):1–3.
Canavan C, Abrams K, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;23(8):1097–104.
Xu Z-S, Zhang H-X, Li W-W, et al. FAM64A positively regulates STAT3 activity to promote Th17 differentiation and colitis-associated carcinogenesis. Proc Natl Acad Sci. 2019;116(21):10447–52.
Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019;20(8):970–9.
Sakaguchi S. Regulatory T cells. Springer Semin Immunopathol. 2006;28(1):1–2.
Clough JN, Omer OS, Tasker S, et al. Regulatory T-cell therapy in Crohn’s disease: challenges and advances. Gut. 2020;69(5):942–52.
Phuong NNT, Palmieri V, Adamczyk A, et al. IL-33 drives expansion of type 2 innate lymphoid cells and regulatory T cells and protects mice from severe, acute colitis. Front Immunol. 2021;12:669787.
Huang L-j, Mao X-t, Li Y-y, et al. Multiomics analyses reveal a critical role of selenium in controlling T cell differentiation in Crohn’s disease. Immunity. 2021. https://doi.org/10.1016/j.immuni.2021.07.004.
Lu Y, Li Y, Liu Q, et al. MondoA-TXNIP axis maintains regulatory T cell identity and function in colorectal cancer microenvironment. Gastroenterology. 2021. https://doi.org/10.1053/j.gastro.2021.04.041.
Erdman SE, Sohn JJ, Rao VP, et al. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ Mice. Can Res. 2005;65(10):3998–4004.
Ibrahim ML, Klement JD, Lu C, et al. Myeloid-derived suppressor cells produce IL-10 to elicit DNMT3b-dependent IRF8 silencing to promote colitis-associated colon tumorigenesis. Cell Rep. 2018;25(11):3036-46.e6.
Wang Y, Ding Y, Deng Y, et al. Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer. J Immunother Cancer. 2020;8(2):e000609.
Corzo CA, Cotter MJ, Cheng P, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182(9):5693–701.
Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Can Res. 2010;70(1):99–108.
Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 2019;25(18):5449–57.
Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3–8.
Kujawski M, Kortylewski M, Lee H, et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Investig. 2008;118(10):3367–77.
Singh UP, Singh NP, Singh B, et al. Role of resveratrol-induced CD11b(+) Gr-1(+) myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3(+) T cells and amelioration of chronic colitis in IL-10(−/−) mice. Brain Behav Immun. 2012;26(1):72–82.
Song J, Chen Z, Geng T, et al. Deleting MyD88 signaling in myeloid cells promotes development of adenocarcinomas of the colon. Cancer Lett. 2018;433:65–75.
Eftychi C, Schwarzer R, Vlantis K, et al. Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment. Immunity. 2019;51(2):367-80.e4.
Zhou J, Huang S, Wang Z, et al. Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation. Nat Commun. 2019;10(1):1–11.
Cui B, Lu S, Lai L, et al. Protective function of interleukin 27 in colitis-associated cancer via suppression of inflammatory cytokines in intestinal epithelial cells. Oncoimmunology. 2017;6(2):e1268309.
Wang T, Fan C, Yao A, et al. The adaptor protein CARD9 protects against colon cancer by restricting mycobiota-mediated expansion of myeloid-derived suppressor cells. Immunity. 2018;49(3):504-14. e4.
Harusato A, Viennois E, Etienne-Mesmin L, et al. Early-life microbiota exposure restricts myeloid-derived suppressor cell–driven colonic tumorigenesis. Cancer Immunol Res. 2019;7(4):544–51.
Dou D, Liang J, Zhai X, et al. Oxytocin signalling in dendritic cells regulates immune tolerance in the intestine and alleviates DSS-induced colitis. Clin Sci. 2021;135(4):597–611.
Abbasi-Kenarsari H, Heidari N, Baghaei K, et al. Synergistic therapeutic effect of mesenchymal stem cells and tolerogenic dendritic cells in an acute colitis mouse model. Int Immunopharmacol. 2020;88:107006.
Berndt BE, Zhang M, Chen G-H, et al. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J Immunol. 2007;179(9):6255–62.
Abe K, Nguyen KP, Fine SD, et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc Natl Acad Sci USA. 2007;104(43):17022–7.
Murai M, Turovskaya O, Kim G, et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol. 2009;10(11):1178–84.
Wei H-X, Wang B, Li B. IL-10 and IL-22 in mucosal immunity: driving protection and Pathology. Front Immunol. 2020;11:1315.
Kaser A, Ludwiczek O, Holzmann S, et al. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol. 2004;24(1):74–85.
Souza HS, Elia CC, Spencer J, et al. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999;45(6):856–63.
Ko H-J, Hong E-H, Cho J, et al. Plasmacytoid dendritic cells regulate colitis-associated tumorigenesis by controlling myeloid-derived suppressor cell infiltration. Cancer Lett. 2020;493:102–12.
De BA, Mende I, Baretton G, et al. A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J Immunol. 2003;170(10):5089–94.
Zheng T, Zhang B, Chen C, et al. Protein kinase p38α signaling in dendritic cells regulates colon inflammation and tumorigenesis. Proc Natl Acad Sci. 2018;115(52):E12313–22.
Kempski J, Giannou AD, Riecken K, et al. IL22BP mediates the antitumor effects of lymphotoxin against colorectal tumors in mice and humans. Gastroenterology. 2020;159(4):1417-303.e3.
Bain CC, Bravo-Blas A, Scott CL, et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol. 2014;15(11):929–37.
He J, Song Y, Li G, et al. Fbxw7 increases CCL2/7 in CX3CR1 hi macrophages to promote intestinal inflammation. J Clin Investig. 2019;129(9):3877–93.
Bain CC, Scott CL, Uronenhansson H, et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 2013;6(3):498–510.
Smith P, Smythies L, Shen R, et al. Intestinal macrophages and response to microbial encroachment. Mucosal Immunol. 2011;4(1):31–42.
Platt AM, Bain CC, Bordon Y, et al. An independent subset of TLR expressing CCR2-dependent macrophages promotes colonic inflammation. J Immunol. 2010;184(12):6843–54.
Aschenbrenner D, Quaranta M, Banerjee S, et al. Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. Gut. 2021;70(6):1023–36.
Kamada N, Hisamatsu T, Okamoto S, et al. Unique CD14+ intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis. J Clin Investig. 2008;118(6):2269–80.
Deng F, He S, Cui S, et al. A molecular targeted immunotherapeutic strategy for ulcerative colitis via dual-targeting nanoparticles delivering miR-146b to intestinal macrophages. J Crohns Colitis. 2019;13(4):482–94.
Wunderlich CM, Ackermann PJ, Ostermann AL, et al. Obesity exacerbates colitis-associated cancer via IL-6-regulated macrophage polarisation and CCL-20/CCR-6-mediated lymphocyte recruitment. Nat Commun. 2018;9(1):1–16.
Mukhopadhyay S, Heinz E, Porreca I, et al. Loss of IL-10 signaling in macrophages limits bacterial killing driven by prostaglandin E2. J Exp Med. 2020;217(2):e20180649.
Mola S, Pandolfo C, Sica A, et al. The macrophages-microbiota interplay in colorectal cancer (CRC)-related inflammation: prognostic and therapeutic significance. Int J Mol Sci. 2020;21(18):6866.
Masato N, Manabu M, Hiroshi S, et al. EP4 receptor-associated protein in macrophages ameliorates colitis and colitis-associated tumorigenesis. PLoS Genet. 2015;11(10):e1005542.
Marelli G, Erreni M, Anselmo A, et al. Heme-oxygenase-1 production by intestinal CX3CR1+ macrophages helps to resolve inflammation and prevents carcinogenesis. Can Res. 2017;77(16):4472–85.
Katholnig K, Schütz B, Fritsch SD, et al. Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis. JCI Insight. 2019;4(20):e124164.
Dai L, Liu Y, Cheng L, et al. SARI attenuates colon inflammation by promoting STAT1 degradation in intestinal epithelial cells. Mucosal Immunol. 2019;12(5):1130–40.
Triner D, Devenport SN, Ramakrishnan SK, et al. Neutrophils restrict tumor-associated microbiota to reduce growth and invasion of colon tumors in mice. Gastroenterology. 2019;156(5):1467–82.
Kühl AA, Kakirman H, Janotta M, et al. Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils. Gastroenterology. 2007;133(6):1882–92.
Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. Front Immunol. 2014;5:508.
Butin-Israeli V, Bui TM, Wiesolek HL, et al. Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing. J Clin Investig. 2019;129(2):712–26.
Tian Y, Xu J, Li Y, et al. MicroRNA-31 reduces inflammatory signaling and promotes regeneration in colon epithelium, and delivery of mimics in microspheres reduces colitis in mice. Gastroenterology. 2019;156(8):2281-96.e6.
Zhou G, Peng K, Song Y, et al. CD177+ neutrophils suppress epithelial cell tumourigenesis in colitis-associated cancer and predict good prognosis in colorectal cancer. Carcinogenesis. 2017;39(2):272–82.
Lin Y, Cheng L, Liu Y, et al. Intestinal epithelium-derived BATF3 promotes colitis-associated colon cancer through facilitating CXCL5-mediated neutrophils recruitment. Mucosal Immunol. 2020;14(D1):1–12.
Zhang Y, Diao N, Lee CK, et al. Neutrophils deficient in innate suppressor IRAK-M enhances anti-tumor immune responses. Mol Ther. 2020;28(1):89–99.
Deng Q, Yao Y, Yang J, et al. AKR1B8 deficiency drives severe DSS-induced acute colitis through invasion of luminal bacteria and activation of innate immunity. Front Immunol. 2022;13:1042549.
Li G-Q, Xia J, Zeng W, et al. The intestinal γδ T cells: functions in the gut and in the distant organs. Front Immunol. 2023;14:1206299.
Wang X, Khoshaba R, Shen Y, et al. Impaired barrier function and immunity in the colon of aldo-keto reductase 1B8 deficient mice. Front Cell Dev Biol. 2021;9:632805.
Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23(1):107–13.
Bhattacharya N, Yuan R, Prestwood TR, et al. Normalizing microbiota-induced retinoic acid deficiency stimulates protective CD8+ T cell-mediated immunity in colorectal cancer. Immunity. 2016;45(3):641–55.
Ryzhakov G, West NR, Franchini F, et al. Alpha kinase 1 controls intestinal inflammation by suppressing the IL-12/Th1 axis. Nat Commun. 2018;9(1):1–13.
Nasef NA, Mehta S. Role of inflammation in pathophysiology of colonic disease: an update. Int J Mol Sci. 2020;21(13):4748.
Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223–37.
Lee JG, Lee Y-R, Lee A-r, et al. Role of the global gut microbial community in the development of colitis-associated cancer in a murine model. Biomed Pharmacother. 2021;135:111206.
Hu S, Vila AV, Gacesa R, et al. Whole exome sequencing analyses reveal gene–microbiota interactions in the context of IBD. Gut. 2021;70(2):285–96.
Vila AV, Imhann F, Collij V, et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med. 2018;10(472):eaap8914.
Yang Y, Li L, Xu C, et al. Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis. Gut. 2021;70(8):1495–506.
Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134(2):577–94.
Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2019;16(6):331–45.
Kudelka MR, Stowell SR, Cummings RD, et al. Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD. Nat Rev Gastroenterol Hepatol. 2020;17(10):597–617.
Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22(2):292–8.
Strauss J, Kaplan GG, Beck PL, et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011;17(9):1971–8.
Yu MR, Kim HJ, Park HR. Fusobacterium nucleatum accelerates the progression of colitis-associated colorectal cancer by promoting EMT. Cancers. 2020;12(10):2728.
Dregelies T, Haumaier F, Sterlacci W, et al. Detection of Fusobacterium nucleatum in patients with colitis-associated colorectal cancer. Curr Microbiol. 2023;80(9):293.
Han JX, Tao ZH, Qian Y, et al. ZFP90 drives the initiation of colitis-associated colorectal cancer via a microbiota-dependent strategy. Gut Microbes. 2021;13(1):1–20.
Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum Increases proliferation of colorectal cancer cells and tumor development in mice by activating TLR4 signaling to NFκB, upregulating expression of microRNA-21. Gastroenterology. 2016;152(4):851.
Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/Î2-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195–206.
Tenaillon O, Skurnik D, Picard B, et al. The population genetics of commensal Escherichia coli. Nat Rev Microbiol. 2010;8(3):207–17.
Arthur JC, Perezchanona E, Mühlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Gut Microbes. 2013;338(3):120–3.
Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, et al. Escherichia coli pathobionts associated with inflammatory bowel disease. Clin Microbiol Rev. 2019;32(2):e00060-e118.
Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology. 2004;127(2):412–21.
Viladomiu M, Metz ML, Lima SF, et al. Adherent-invasive E. coli metabolism of propanediol in Crohn’s disease regulates phagocytes to drive intestinal inflammation. Cell Host Microbe. 2021;29(4):607-19.e8.
Eavespyles T, Allen CA, Taormina J, et al. Escherichia coli isolated from a Crohn’s disease patient adheres, invades, and induces inflammatory responses in polarized intestinal epithelial cells. Int J Med Microbiol. 2008;298(5–6):397–409.
Cevallos SA, Lee J-Y, Tiffany CR, et al. Increased epithelial oxygenation links colitis to an expansion of tumorigenic bacteria. MBio. 2019. https://doi.org/10.1128/mbio.
Isolauri E, Salminen S. Probiotics: use in allergic disorders: a nutrition, allergy, mucosal immunology, and intestinal microbiota (NAMI) research group report. J Clin Gastroenterol. 2008;42:S91–6.
Silveira DSC, Veronez LC, Lopes-Júnior LC, et al. Lactobacillus bulgaricus inhibits colitis-associated cancer via a negative regulation of intestinal inflammation in azoxymethane/dextran sodium sulfate model. World J Gastroenterol. 2020;26(43):6782.
Bedada TL, Feto TK, Awoke KS, et al. Probiotics for cancer alternative prevention and treatment. Biomed Pharmacother. 2020;129:110409.
Cousin FJ, Jouanlanhouet S, Corcos L, et al. Milk fermented by Propionibacterium freudenreichii induces apoptosis of HGT-1 human gastric cancer cells. PLoS ONE. 2012;7(3):e31892.
Iwama T, Fujiya M, Konishi H, et al. Bacteria-derived ferrichrome inhibits tumor progression in sporadic colorectal neoplasms and colitis-associated cancer. Cancer Cell Int. 2021;21(1):1–15.
Zhong XZ, Covasa M. Emerging roles of lactic acid bacteria in protection against colorectal cancer. World J Gastroenterol. 2014;20(24):7878–86.
Zhao Y, Jiang Q. Roles of the polyphenol-gut microbiota interaction in alleviating colitis and preventing colitis-associated colorectal cancer. Adv Nutr. 2021;12(2):546–65.
Oh NS, Lee JY, Kim Y-T, et al. Cancer-protective effect of a synbiotic combination between Lactobacillus gasseri 505 and a Cudrania tricuspidata leaf extract on colitis-associated colorectal cancer. Gut microbes. 2020;12(1):1785803.
van der Giessen J, Binyamin D, Belogolovski A, et al. Modulation of cytokine patterns and microbiome during pregnancy in IBD. Gut. 2020;69(3):473–86.
Choi JH, Moon CM, Shin T-S, et al. Lactobacillus paracasei-derived extracellular vesicles attenuate the intestinal inflammatory response by augmenting the endoplasmic reticulum stress pathway. Exp Mol Med. 2020;52(3):423–37.
Takagi A, Ikemura H, Matsuzaki T, et al. Relationship between the in vitro response of dendritic cells to Lactobacillus and prevention of tumorigenesis in the mouse. J Gastroenterol. 2008;43(9):661–9.
Greving CNA, Towne JE. A role for IL-12 in IBD after all? Immunity. 2019;51(2):209–11.
Jacouton E, Chain F, Sokol H, et al. Probiotic strain Lactobacillus casei BL23 prevents colitis-associated colorectal cancer. Front Immunol. 2017;8:1553.
He R, Han C, Li Y, et al. Cancer-preventive role of bone marrow-derived mesenchymal stem cells on colitis-associated colorectal cancer: roles of gut microbiota involved. Front Cell Dev Biol. 2021;9:610.
Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017;67(4):326–44.
Helmink BA, Khan MW, Hermann A, et al. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377–88.
Hwang S, Jo M, Hong JE, et al. Protective effects of zerumbone on colonic tumorigenesis in enterotoxigenic bacteroides fragilis (ETBF)-colonized AOM/DSS BALB/c mice. Int J Mol Sci. 2020;21(3):857.
Akutko K, Stawarski A. Probiotics, prebiotics and synbiotics in inflammatory bowel diseases. J Clin Med. 2021;10(11):2466.
Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152(2):327-39.e4.
Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66(6):1039–48.
Downward JRE, Falkowski NR, Mason KL, et al. Modulation of post-antibiotic bacterial community reassembly and host response by Candida albicans. Sci Rep. 2013;3(1):1–11.
De Luca A, Zelante T, D’angelo C, et al. IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol. 2010;3(4):361–73.
Jostins L, Ripke S, Weersma RK, et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–24.
Malik A, Sharma D, Malireddi RS, et al. SYK-CARD9 signaling axis promotes gut fungi-mediated inflammasome activation to restrict colitis and colon cancer. Immunity. 2018;49(3):515-30.e5.
Limon JJ, Tang J, Li D, et al. Malassezia is associated with Crohn’s disease and exacerbates colitis in mouse models. Cell Host Microbe. 2019;25(3):377-88.e6.
Tang J, Iliev ID, Brown J, et al. Mycobiome: approaches to analysis of intestinal fungi. J Immunol Methods. 2015;421:112–21.
Ohnmacht AJ, Stahler A, Stintzing S, et al. The oncology biomarker discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer. Nat Commun. 2023;14(1):5391.
Gang W, Wang JJ, Guan R, et al. Strategy to targeting the immune resistance and novel therapy in colorectal cancer. Cancer Med. 2018;7(5):1578–603.
Nardone OM, Zammarchi I, Santacroce G, et al. Inflammation-driven colorectal cancer associated with colitis: from pathogenesis to changing therapy. Cancers. 2023;15(8):2389.
Yang C, Song J, Hwang S, et al. Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells. Redox Biol. 2021;47:102144.
Li M, Xia M, Zhang Z, et al. METTL3 antagonizes 5-FU chemotherapy and confers drug resistance in colorectal carcinoma. Int J Oncol. 2022;61(3):1–13.
Dong S, Liang S, Cheng Z, et al. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. J Exp Clin Cancer Res. 2022;41(1):1–27.
Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Long non coding RNA Biology. Berlin: Springer; 2017. p. 1–46.
Kim N, Cho D, Kim H, et al. Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab. Int J Cancer. 2020;146(8):2194–200.
Martinelli E, Ciardiello D, Martini G, et al. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol. 2020;31(1):30–40.
Parseghian C, Loree J, Morris V, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30(2):243–9.
Srivatsa S, Paul MC, Cardone C, et al. EGFR in tumor-associated myeloid cells promotes development of colorectal cancer in mice and associates with outcomes of patients. Gastroenterology. 2017;153(1):178-90.e10.
Wang H, Li Y, Shi G, et al. A novel antitumor strategy: simultaneously inhibiting angiogenesis and complement by targeting VEGFA/PIGF and C3b/C4b. Mol Ther Oncolytics. 2020;16:20–9.
Zhu H, Liu X. Advances of tumorigenesis, diagnosis at early stage, and cellular immunotherapy in gastrointestinal malignancies. Front Oncol. 2021;11:666340.
Shek D, Akhuba L, Carlino MS, et al. Immune-checkpoint inhibitors for metastatic colorectal cancer: a systematic review of clinical outcomes. Cancers. 2021;13(17):4345.
Payandeh Z, Khalili S, Somi MH, et al. PD-1/PD-L1-dependent immune response in colorectal cancer. J Cell Physiol. 2020;235(7–8):5461–75.
Choucair K, Radford M, Bansal A, et al. Advances in immune therapies for the treatment of microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer. Int J Oncol. 2021;59(3):1–17.
Sun L, Patai ÁV, Hogenson TL, et al. Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer. Oncogene. 2021;40(32):5105–15.
Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1(1):32–42.
Perez-Ruiz E, Minute L, Otano I, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569(7756):428–32.
Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):1–12.
Kamal AM, Wasfey EF, Elghamry WR, et al. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes. Clin Biochem. 2021;96:13–8.
Sasidharan Nair V, Toor SM, Taha RZ, et al. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin Epigenetics. 2018;10(1):1–9.
Zaravinos A, Roufas C, Nagara M, et al. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. J Exp Clin Cancer Res. 2019;38(1):1–18.
Koelink PJ, Bloemendaal FM, Li B, et al. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut. 2020;69(6):1053–63.
Aden K, Rehman A, Waschina S, et al. Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases. Gastroenterology. 2019;157(5):1279-9211.e11.
Lee JWJ, Plichta D, Hogstrom L, et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe. 2021;29(8):1294-1304.e4.
Yakymenko O, Schoultz I, Gullberg E, et al. Infliximab restores colonic barrier to adherent-invasive E. coli in Crohn’s disease via effects on epithelial lipid rafts. Scand J Gastroenterol. 2018;53(6):677–84.
Waldner MJ, Neurath MF. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin Immunol. 2014;26(1):75–9.
Patnaude L, Mayo M, Mario R, et al. Mechanisms and regulation of IL-22-mediated intestinal epithelial homeostasis and repair. Life Sci. 2021;271:119195.
Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310(3):G155–62.
Zorzi F, Calabrese E, Di Fusco D, et al. High Smad7 in the early post-operative recurrence of Crohn’s disease. J Transl Med. 2020;18(1):1–8.
Troncone E, Marafini I, Stolfi C, et al. Involvement of Smad7 in inflammatory diseases of the gut and colon cancer. Int J Mol Sci. 2021;22(8):3922.
Garcia-Arranz M, Herreros MD, Gonzalez-Gomez C, et al. Treatment of Crohn’s-related rectovaginal fistula with allogeneic expanded-adipose derived stem cells: a phase I-IIa clinical trial. Stem Cells Transl Med. 2016;5(11):1441–6.
Shen Z, Huang W, Liu J, et al. Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases. Front Immunol. 2021;12:749192.
Liu H, Liang Z, Wang F, et al. Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism. JCI Insight. 2019;4(24):e131273.
Tyler CJ, Guzman M, Lundborg LR, et al. Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis. Mucosal Immunol. 2021;15(1):109–19.
Keir ME, Fuh F, Ichikawa R, et al. Regulation and Role of αE integrin and gut homing Integrins in migration and retention of intestinal lymphocytes during inflammatory bowel disease. J Immunol. 2021;207(9):2245–54.
Wang X, Chen S, Xiang H, et al. Role of sphingosine-1-phosphate receptors in vascular injury of inflammatory bowel disease. J Cell Mol Med. 2021;25(6):2740–9.
Scarozza P, Schmitt H, Monteleone G, et al. Oligonucleotides—a novel promising therapeutic option for IBD. Front Pharmacol. 2019;10:314.
Britton GJ, Contijoch EJ, Spindler MP, et al. Defined microbiota transplant restores Th17/RORγt+ regulatory T cell balance in mice colonized with inflammatory bowel disease microbiotas. Proc Natl Acad Sci. 2020;117(35):21536–45.
Chung Y, Ryu Y, An BC, et al. A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota. Microbiome. 2021;9(1):1–17.
Uchiyama K, Naito Y, Takagi T. Intestinal microbiome as a novel therapeutic target for local and systemic inflammation. Pharmacol Ther. 2019;199:164–72.
Add Comment